Start an analysis for ALLR
Allarity Therapeutics, Inc.
Stock · NASDAQProgram summary
| Field | Value | As of | Source |
|---|---|---|---|
| Current authorization | $5m | 30-Sep-26 | 10-Q filed 13-Nov-26 |
| Remaining authorization | $5m | 30-Sep-26 | 10-Q filed 13-Nov-26 |
| Program expiry | 01-Mar-27 | 30-Sep-26 | 10-Q filed 13-Nov-26 |
| Repurchased last quarter | $0 | 30-Sep-26 | 10-Q filed 13-Nov-26 |
| Has used an ASR | No | — |
Programs
| Authorized on | Authorized | Remaining | Expires | Terms |
|---|---|---|---|---|
| 26-Feb-26 | $5m | $5m | 01-Mar-27 | On February 26, 2026, the board of directors approved a new share repurchase program ("the 2026 Share Repurchase Plan"), with authorization to purchase up to $5 million of the Company's outstanding shares of common stock over a twelve-month period ending March 1, 2027.10-Q filed 13-Nov-26 |
Open-market repurchases
- Jul ’26
- Aug ’26
- Sep ’26
| Month ended | Shares | Avg price | ≈ Value | Source |
|---|---|---|---|---|
| 30-Sep-26 | 0 | — | $0 | 10-Q filed 13-Nov-26 |
| 31-Aug-26 | 0 | — | $0 | 10-Q filed 13-Nov-26 |
| 31-Jul-26 | 0 | — | $0 | 10-Q filed 13-Nov-26 |